Skip to main content

Advertisement

Log in

Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 μl) blood samples

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

The present study aims to establish a method that provides fast, precise and reproducible pharmacokinetic (PK) parameters of antibody-calicheamicin conjugates. The method should discriminate between PK of the antibody moiety and PK of the conjugated calicheamicin (CM).

Methods

The conjugates gemtuzumab ozogamicin (CMA-676, Mylotarg®) or inotuzumab ozogamicin (CMC-544) were injected in the tail vein of nude mice. At regular time intervals, 5 μl whole blood samples were taken from the tail artery. Concentrations of conjugated CMA-676 or CMC-544 as well as concentrations of their respective antibody moiety were determined by sandwich plasmon resonance. This detection system measures changes in the plasma resonance angle caused by the interaction of macromolecules on biosensor chips. We determined as a first measure the binding of CMA-676 or CMC-544 to their respective antigens, CD33 or CD22. As a second measure we determined the amount of CM on the antigen-bound conjugates. This was done by determination of changes in plasma resonance angle after binding of an anti-CM antibody.

Results

Sandwich plasmon resonance allowed detection of both conjugates in blood of mice in a range of 100–1,000 ng/ml protein. Due to the precision of the sampling and detection methods, PK values of each conjugate were determined in individual mice. Calicheamicin bound to antibody was eliminated faster than the antibody alone. The presence of a CD22-expressing tumour in mice reduced the plasma levels of the CD22-targeting conjugate but not of the CD33-targeting one.

Conclusions

Using small blood samples from a mouse, the sandwich plasmon resonance method provided PK-values of CM-conjugates and information about the stability of the linkage in vivo. Comparison between the PK-values of CM-conjugates in tumour-bearing and tumour-free mice suggested that retention of the conjugate in tumour tissue due to antigen targeting could be deduced from the plasma levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody for relapsed indolent lymphoma: half of the patients respond to a four-dose treatment program. J Clin Oncol 16:2825–2833

    PubMed  CAS  Google Scholar 

  2. Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-Lopez AJ, White CA (2002) Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99:4336–4342

    Article  PubMed  CAS  Google Scholar 

  3. Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, Shannon-Dorcy K, Berger MS, Bernstein ID (1999) Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93:3678–3684

    PubMed  CAS  Google Scholar 

  4. Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev 5:147–159

    CAS  Google Scholar 

  5. Graff CP, Wittrup KD (2003) Theoretical analysis of antibody targeting of tumour spheroids: importance of dosage for penetration and affinity for retention. Cancer Res 63:1288–1296

    PubMed  CAS  Google Scholar 

  6. Karlsson R, Michaelsson A, Mattsson L (1991) Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J Immunol Methods 145:229–240

    Article  PubMed  CAS  Google Scholar 

  7. Johne B, Gadnell M, Hansen K (1993) Epitope mapping and binding kinetics of monoclonal antibodies studied by real time interaction analysis using surface plasmon resonance. J Immunol Methods 160:191–198

    Article  PubMed  CAS  Google Scholar 

  8. DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, Kunz A, Hamann PR, Gorovits B, Udata C, Moran J, Popplewell AG, Stephens S, Frost P, Damle NK (2004) Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103(5):1807–1814

    Article  PubMed  CAS  Google Scholar 

  9. Boghaert ER, Khandke K, Sridharan L, Armellino D, Dougher M, DiJoseph JF, Kunz A, Hamann PR, Sridharan A, Jones S, Discafani C, Damle NK (2006) Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy. Int J Oncol 28:675–684

    PubMed  CAS  Google Scholar 

  10. Johne B, Hansen K, Mørk E, Hotlund J (1995) Colloidal gold conjugated monoclonal antibodies, studied in the BIAcore biosensor and in Nycocard immunoassay format. J Immunol Methods 183:167–174

    Article  PubMed  CAS  Google Scholar 

  11. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel-Dekker. New York

    Google Scholar 

  12. Mason S, La S, Mytych D, Swanson SJ, Ferbas J (2003) Validation of the BIACORE 3000 platform for detection of antibodies against erythropoietic agents in human serum samples. Curr Med Res Opin 19:651–659

    Article  PubMed  CAS  Google Scholar 

  13. Pearson JE, Kane JW, Petrarki-Kallioti I, Gill A, Vadgama P (1998) Surface plasmon resonance: a study of the effect of biotinylation on the selection of antibodies for use in immunoassays. J Immunol Methods 221:87–94

    Article  PubMed  CAS  Google Scholar 

  14. Xie H, Audette C, Hoffee M, Lambert JM, Blättler WA (2004) Pharmacokinetics and biodistribution of the antitumor conjugate, Cantuzumab Mertansine (huC242-DM1), and its two components in mice. J Pharmacol Exp Ther 308:1073–1082

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

The authors thank Dr. Roger French for the statistical analysis of the data.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kiran M. Khandke.

Additional information

Erwin R. Boghaert and Kiran M. Khandke contributed equally to the presented results.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boghaert, E.R., Khandke, K.M., Sridharan, L. et al. Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 μl) blood samples. Cancer Chemother Pharmacol 61, 1027–1035 (2008). https://doi.org/10.1007/s00280-007-0560-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-007-0560-2

Keywords

Navigation